BARRIE, ON, April 13, 2023 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs", "MediPharm" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to provide an update on significant progress made on the integration of VIVO Cannabis Inc.'s ("VIVO") operations following the completion of its plan of arrangement with VIVO, pursuant to which MediPharm acquired all of the issued and outstanding common shares of VIVO in an all-equity business combination transaction effective April 1, 2023 (the "Transaction").
Read more at newswire.caProvided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.